prednisone and Lymphoma, Follicular studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Lymphoma, Follicular: Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.

Research Excerpts

Excerpt	Relevance	Reference
"Lenalidomide has response rates of 45% in relapsed transformed DLBCL."	7.01	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. ( Ansell, SM; Desai, SH; Habermann, TM; Inwards, DJ; Johnston, PB; King, RL; LaPlant, B; Macon, WR; Micallef, I; Nowakowski, GS; Porrata, LF; Wang, Y; Witzig, TE, 2021)
"Bortezomib has demonstrated efficacy in patients with relapsed B-cell non-Hodgkin lymphoma (NHL) both alone and in combination with other agents; however, limited data exist regarding its toxicity in combination with common frontline therapies for indolent NHL."	6.77	A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. ( Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M, 2012)
"To evaluate the effect of epirubicin on therapeutic response and survival in patients with indolent nonfollicular B-cell lymphomas (INFL) treated with pulsed high-dose chlorambucil."	5.10	Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. ( Baldini, L; Brugiatelli, M; Cavanna, L; Colombi, M; Federico, M; Gobbi, P; Goldaniga, M; Liberati, M; Lombardo, M; Luminari, S; Merli, F; Morabito, F; Sacchi, S; Silingardi, V; Stelitano, C, 2003)
"Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma."	4.91	A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. ( Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE, 2015)
"For patients with follicular lymphoma, these figures were 72% and 80%, respectively."	3.80	Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. ( Ayala, A; Cabanillas, F; Cox, JD; Fuller, LM; Ha, CS; Hagemeister, FB; Hess, M; Manning, JT; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Seymour, JF; Smith, TL, 2003)
" Therapy with oral prednisone easily controlled her skin rash but she had profuse diarrhea that did not respond to high dose intravenous corticosteroids and denileukin diftitox."	3.73	Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. ( Bierbaum, W; Hamadani, M; Maqbool, F; Selby, G; Tfayli, A, 2006)
" Congestive heart failure resulting in death occurred in one case given 315mg /m2 of adriamycin and then 90 mg/m2 of mitoxantrone."	3.67	[Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report]. ( Hattori, M; Honda, T; Sampi, K, 1984)
"Lenalidomide has response rates of 45% in relapsed transformed DLBCL."	3.01	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. ( Ansell, SM; Desai, SH; Habermann, TM; Inwards, DJ; Johnston, PB; King, RL; LaPlant, B; Macon, WR; Micallef, I; Nowakowski, GS; Porrata, LF; Wang, Y; Witzig, TE, 2021)
"The prognosis and treatment options for follicular lymphoma (FL) remain heterogenous."	3.01	Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study. ( Gui, L; He, X; Liu, P; Qin, Y; Shi, Y; Yang, J; Yang, S; Zhang, C; Zhou, L; Zhou, S; Zhou, Y, 2021)
" We hypothesised that ex vivo expanded lymphokine-activated killer (LAK) cells administered to FL-remission patients are safe and improve anti-CD20 efficacy."	2.94	Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression. ( Andrade-Campos, M; Bandrés, E; Feliu, J; García-Muñoz, R; Giraldo, P; Grande, C; Inogés, S; López-Díaz de Cerio, A; Martínez-Calle, N; Núñez-Córdoba, JM; Olave, MT; Panizo, Á; Panizo, C; Pena, E; Rodríguez-Calvillo, M, 2020)
"About 283 (89%) patients had follicular lymphoma, 30 (9%) marginal-zone lymphoma and six (2%) other subtypes."	2.94	Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study. ( Burbury, K; Cheah, CY; Chin, CK; Dickinson, MJ; Fayad, LE; Feng, L; Flowers, CR; Fowler, NH; Hagemeister, FB; Jain, P; Lewis, K; Lim, KJ; Nastoupil, LJ; Neelapu, SS; Qing, Y; Ritchie, D; Samaniego, F; Seymour, JF; Tam, CS; Westin, JR, 2020)
"Lenalidomide in combination with R-CHOP had an acceptable safety profile and showed anti-cancer activity in patients with previously untreated high burden follicular lymphoma."	2.87	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. ( Becker, S; Bouabdallah, R; Cabeçadas, J; Casasnovas, O; Feugier, P; Gabarre, J; Gouill, SL; Haioun, C; Jardin, F; Lamy, T; Molina, TJ; Morschhauser, F; Mounier, N; Salles, G; Tilly, H; Tournilhac, O, 2018)
"Front-line treatment for follicular lymphoma has evolved with the introduction of maintenance therapy, bendamustine (Benda), obinutuzumab (G), and lenalidomide (Len)."	2.82	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. ( Habermann, TM; Maurer, MJ; Nowakowski, GS; Qi, X; Wang, ML; Wang, Y; Witzig, TE; Yang, F; Zhou, S, 2022)
"Follicular lymphoma is an indolent lymphoma that remains incurable with standard approaches."	2.82	Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose? ( Ngu, H; Okosun, J; Phillips, T; Sehn, LH; Takiar, R, 2022)
" Fifty-three patients withdrew after cycle 1; 10 for grade 3 or 4 IRRs and one for a grade 3 adverse event."	2.79	Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. ( Brewster, M; Chai, A; Dakhil, S; Gregory, SA; Hermann, R; Hurst, D; Monte, M; Richards, P; Schreeder, MT; Windsor, KS, 2014)
"Also, the Follicular Lymphoma International Prognostic Index (FLIPI) score increased in 18% (26 of 142) and decreased in 6% (9 of 142) of patients."	2.78	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. ( Arcaini, L; Biasoli, I; Boccomini, C; Carella, AM; D'Arco, AM; Di Raimondo, F; Federico, M; Ferreri, AJ; Gaidano, G; Gallamini, A; Luminari, S; Mastronardi, S; Merli, F; Musto, P; Rusconi, C; Santoro, A; Spina, M; Versari, A; Zinzani, PL, 2013)
"Long-term follow up of patients with follicular lymphoma treated in the FL2000 study confirms the sustained clinical benefit of rituximab without long-term toxicity."	2.78	Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. ( Audhuy, B; Bachy, E; Belhadj, K; Brice, P; Brousse, N; Cartron, G; Delwail, V; Fermé, C; Feugier, P; Foussard, C; Houot, R; Le Gouill, S; Lefort, S; Maisonneuve, H; Morschhauser, F; Salles, G; Sebban, C; Sonet, A, 2013)
"Advanced follicular lymphomas (FL) are considered incurable with conventional chemotherapy and there is no consensus on the best treatment approach."	2.78	Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. ( Braziel, RM; Cheson, BD; Czuczman, MS; Dakhil, SR; Fisher, RI; Friedberg, JW; Gopal, AK; Kaminski, M; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Rimsza, LM; Spier, C; Unger, JM, 2013)
"Bortezomib has demonstrated efficacy in patients with relapsed B-cell non-Hodgkin lymphoma (NHL) both alone and in combination with other agents; however, limited data exist regarding its toxicity in combination with common frontline therapies for indolent NHL."	2.77	A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. ( Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M, 2012)
"An international, Phase II trial was conducted to assess two doses of ofatumumab, a human CD20 monoclonal antibody, combined with cyclophosphamide (750 mg/m(2) ), doxorubicin (50 mg/m(2) ), prednisone (100 mg days 3-7) and vincristine (1·4 mg/m(2) ) (O-CHOP), as frontline treatment for follicular lymphoma (FL)."	2.77	Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. ( Czuczman, MS; Gadeberg, OV; Goldstein, N; Gupta, I; Hess, G; Jewell, RC; Lin, TS; Lisby, S; Pedersen, LM; Strange, C; Viardot, A; Windfeld, K, 2012)
"Bortezomib has demonstrated promising activity in patients with follicular lymphoma (FL)."	2.76	Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. ( Basi, S; Cantin, G; Chen, BE; Couban, S; Crump, M; Djurfeldt, M; Gascoyne, RD; Imrie, K; Lemieux, B; MacDonald, D; Rubin, S; Rubinger, M; Sehn, LH; Shepherd, L; Sussman, J, 2011)
"Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL)."	2.76	Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. ( Ansell, SM; Habermann, TM; Inwards, DJ; Johnston, PB; Klebig, RR; LaPlant, B; Macon, WR; Micallef, IN; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Witzig, TE, 2011)
"Of 79 evaluable patients, 58 (73%) had follicular lymphoma, 13 (16%) mantle cell lymphoma and 8 (10%) lymphoplasmacytic lymphoma."	2.73	Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. ( Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M, 2007)
"A total of 164 patients with follicular lymphoma (grade 1/2), mantle cell lymphoma or lymphoplasmacytic lymphoma (immunocytoma) was randomised to treatment with vincristine 2 mg (day 1) and prednisone 100 mg/m2 (days 1-5) + bendamustine 60 mg/m2 (days 1-5) or + cyclophosphamide 400 mg/m2 (days 1-5) for a total of eight 21-day cycles."	2.72	Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). ( Arzberger, H; Boewer, C; Bremer, K; Dachselt, K; Franke, A; Freund, M; Fricke, HJ; Hahnfeld, S; Herold, M; Ismer, B; Klinkenstein, C; Müller, C; Niederwieser, D; Pasold, R; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Schwarzer, A; Weniger, J; Winkelmann, C, 2006)
"In patients with advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades."	2.72	Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell ly ( Dreyling, M; Hiddemann, W; Hoster, E; Lengfelder, E; Nickenig, C; Pfreundschuh, M; Reiser, M; Trumper, L; Unterhalt, M; Wandt, H, 2006)
"Advanced follicular lymphoma (FL) is incurable with conventional chemotherapy and radiotherapy, and optimal front-line management is controversial."	2.72	Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. ( Braziel, RM; Fisher, RI; Leblanc, M; Maloney, DG; Miller, TP; Press, OW; Unger, JM, 2006)
"Sixty-five patients with Stage I to III follicular lymphoma were randomized."	2.71	A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. ( Cabanillas, F; Cox, JD; Ha, CS; Lee, MS; McLaughlin, P; Mesina, OM; Rodriguez, MA; Romaguera, JE; Tucker, SL; Younes, A, 2005)
" The dosage or drugs chosen for salvage therapy are limited by doxorubicin-induced cardiomyopathy."	2.71	Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin ( Hayama, M; Higashihara, M; Kajiwara, K; Khori, M; Niitsu, N; Tamaru, J, 2005)
"Promising new therapeutic options for follicular lymphoma (FL) include fludarabine plus mitoxantrone (FM) and the mouse/human anti-CD20 antibody, rituximab."	2.71	Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. ( Alinari, L; Baccarani, M; Ciccone, F; De Renzo, A; Falini, B; Fattori, PP; Gentilini, P; Gobbi, M; Guardigni, L; Lauta, VM; Martelli, M; Molinari, AL; Perrotti, A; Pileri, S; Pulsoni, A; Soverini, S; Storti, S; Tucci, A; Tura, S; Zaja, F; Zinzani, PL, 2004)
"Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy."	2.71	A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. ( Braziel, RM; Fisher, RI; Gaynor, ER; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Rivkin, SE; Unger, JM, 2003)
" Thus the goal was first to reduce tumour burden using the CHOP regimen as induction treatment followed by consolidation with rituximab administered on a standard 4 wk schedule at a dosage of 375 mg m-2 body surface area."	2.70	Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. ( Brezinschek, R; Höfler, G; Jäeger, G; Linkesch, W; Neumeister, P; Quehenberger, F; Sill, H, 2002)
"The best treatment of follicular lymphoma remains to be determined because the long natural history of follicular lymphoma requires mature data for accurate analysis."	2.70	Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma. ( Avilés, A; Cleto, S; Díaz, N; Díaz-Maqueo, JC; García, EL; Neri, N; Talavera, A, 2001)
" IFNalpha was withdrawn because of toxicity in 10% of the patients, and a dosage reduction or temporary suspension was required in 28%."	2.69	Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. ( Bouabdallah, R; Brice, P; Brousse, N; Coiffier, B; Doyen, C; Gabarre, J; Haïoun, C; Lepage, E; Pignon, B; Rossi, JF; Solal-Céligny, P; Tendler, CL; Tertian, G, 1998)
" After randomization, 123 patients also received interferon alfa-2b at a dosage of 5 million units three times weekly for 18 months."	2.67	Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. ( Bosly, A; Brice, P; Brousse, N; Haioun, C; Lepage, E; Leporrier, M; Parlier, Y; Peuchmaur, M; Reyes, F; Solal-Celigny, P, 1993)
"Here we report two cases of follicular lymphoma that transformed to CD30 positive diffuse large B cell lymphoma and review the literature on this topic."	2.52	CD 30-positive transformed follicular lymphoma: two case reports and literature review. ( Batlle, A; Climent, F; Colorado, M; Conde, E; Espiga, CR; González Barca, EM; González de Villambrosía, S; Insunza, A; Martin-Sánchez, G; Montes-Moreno, S; Pané-Foix, M; Piris, MA, 2015)
"As with other indolent lymphomas, follicular lymphoma is felt to be highly treatable, but ultimately incurable."	2.49	The optimal management of follicular lymphoma: an evolving field. ( Cheson, BD; Ujjani, C, 2013)
"Thus, the myelofibrosis was reversible."	2.49	[Follicular lymphoma complicated with myelofibrosis and macroglobulinemia at initial presentation]. ( Abe, T; Fujii, S; Fujita, M; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Murase, K; Nagashima, K; Sakurai, T; Sato, M; Yamada, M; Yoshida, M, 2013)
"Here, we present two follicular lymphoma patients; one transformed to THL, another transformed to DHL."	2.49	Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review. ( Sun, B; Wang, Y; Xu, X; Zhang, L; Zhang, Q; Zhang, Y, 2013)
"A pathological diagnosis of follicular lymphoma (FL), grade 3A, was made based on a biopsy specimen from the right inguinal lymph node."	2.47	CD5-positive follicular lymphoma: a case report and literature review. ( Ichikawa, K; Imai, H; Komatsu, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Wakabayashi, M, 2011)
"After diffuse large B-cell lymphoma, follicular lymphoma is the most frequent non-Hodgkin's lymphoma."	2.45	[Current treatment of follicular lymphoma]. ( Beguin, Y; Bonnet, C; de Leval, L; Deprijck, B; Fillet, G, 2009)
"Low-grade and follicular lymphomas account for approximately 40% of the incidences of NHL in the United States."	2.41	Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. ( Benyunes, M; Bernstein, SH; Bernstein, ZP; Brown, K; Czuczman, MS; Fallon, A; Grillo-López, AJ; Klippenstein, D; Loud, P; McCarthy, P; Miller, K; Mohr, A; Rock, MK; Skipper, M; Stewart, C; Wentling, D, 2002)
"We reviewed all reported cases of Burkitt's lymphoma and/or Burkitt's leukemia (BLL) occurring following therapy for Hodgkin's disease."	2.39	Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. ( Cooper, DL; Levy, A; Salloum, E; Tallini, G, 1996)
"Pathological diagnosis was non-Hodgkin follicular lymphoma of mixed small cleaved and large cell type with lymph node metastasis (2/23)."	2.38	[Retroperitoneal malignant lymphoma showing follicular type: report of a case]. ( Asakura, S; Fujii, Y; Hirokawa, M; Ikeda, I; Iwabuchi, K; Maeda, T; Masuda, M; Terao, T, 1992)
"Rituximab (R) or obinutuzumab (G) combined with CHOP chemotherapy are used in previously untreated follicular lymphoma (FL)."	1.91	Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma. ( Boulanger, C; Claustre, G; Durot, E; Etienne-Selloum, N; Fornecker, LM; Graff, V; Maloisel, F; Slimano, F, 2023)
"A lymph node biopsy revealed follicular lymphoma (FL), grade 1."	1.91	[Effective therapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy with obinutuzumab for follicular lymphoma in leukemic phase]. ( Ishiyama, M; Itoi, S; Izuka, Y; Kato, Y; Nagashima, Y; Onizuka, H; Osanai, S; Oshima, S; Ryuzaki, M; Shinohara, A; Shiseki, M; Tanaka, J; Tanaka, N; Yoshinaga, K, 2023)
"Nodular Lymphocyte predominant Hodgkin lymphoma (NLPHL) are rare lymphomas in pediatric patients comprising less than 10 % of all Hodgkin lymphoma (HL)."	1.91	[Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma]. ( Boudjemaa, S; Dourthe, ME; Ducou Le Pointe, H; Garnier, N; Haouy, S; Jo Molina, T; Landman-Parker, J; Leblanc, T; Minard-Colin, V; Montravers, F; Rigaud, C; Simonin, M, 2023)
"Follicular lymphoma is the second most common type of non-Hodgkin lymphoma, and the disease course is usually characterized by an indolent clinical course."	1.72	Management of elderly patients with malignant lymphoma. ( Miyazaki, K, 2022)
"EZH2 is mutated in nearly 25% of follicular lymphoma (FL) cases."	1.72	EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. ( Bastos Oreiro, M; Buño, I; Carbonell, D; Chicano, M; Díaz Crespo, FJ; Diez Martín, JL; Kwon, M; Martín Rojas, R; Martínez-Laperche, C; Menárguez, J; Muñiz, P; Sanz-Villanueva, L; Suárez-González, J, 2022)
"However, data in follicular lymphoma (FL) are scarce."	1.62	Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma. ( Aróstegui, JI; Bataller, A; Bladé, J; Campo, E; Cibeira, MT; Correa, JG; Delgado, J; Fabregat, A; Fernández de Larrea, C; Giné, E; López-Guillermo, A; Magnano, L; Mozas, P; Nadeu, F; Oliver, A; Piñeyroa, JA; Rivas-Delgado, A; Rivero, A; Rosiñol, L; Villamor, N, 2021)
"Similar to classic follicular lymphoma, patients presented most often with low-grade (1-2) but high-stage (III-IV) disease with absence of B symptoms; however, overall survival was worse than that of traditional follicular lymphoma."	1.56	Double-Hit and Triple-Hit Follicular Lymphoma. ( Asakrah, S; Weinstock, M; Wolf, Z; Ziemba, JB, 2020)
"Based on centroblast frequency, follicular lymphoma (FL) is subdivided into grades 1-2, 3A, and 3B."	1.56	First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis. ( Böttcher, S; Hauf, E; Herold, M; Hirt, C; Kahl, C; Kämpfe, D; Keller, U; Klapper, W; Koch, K; Kroschinsky, F; La Rosée, P; Marks, R; Maschmeyer, G; Meissner, J; Meyer, A; Monecke, A; Pouyiourou, M; Prange-Krex, G; Schmalenberg, H; Scholz, CW; Stroux, A; Viardot, A; Vucinic, V; Weber, T; Witzens-Harig, M, 2020)
"However, in subset analyses of follicular lymphoma (FL), the results were incongruent."	1.56	Pretreatment SUV ( Ahmed, MA; Ahmed, S; Davis, RE; Fayad, LE; Feng, L; Flowers, CR; Fowler, NH; Hagemeister, FB; Iyer, SP; Lee, HJ; Nair, R; Nastoupil, LJ; Neelapu, SS; Noorani, M; Parmar, S; Rodriguez, MA; Samaniego, F; Steiner, RE; Strati, P; Wang, M; Westin, JR, 2020)
" Rituximab (R) was added 10 days later without incident, and the patient completed six cycles of the R-CHOP therapy without adverse events."	1.56	Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction. ( Hara, T; Ikeda, Y; Matsumoto, R; Murayama, M; Ohno, A; Sobajima, T; Sugiyama, Y; Suzuki, R; Tsurumi, H; Yamada, R; Yamagishi, Y; Yamakawa, K, 2020)
"Brainstem encephalitis has been described occurring after infection from enteroviruses, more commonly in the paediatric population, but also in immunosuppressed adults."	1.51	Brainstem encephalitis caused by Coxsackie A16 virus in a rituximab-immunosuppressed patient. ( Andresen, D; Cameron Smail, R; O'Neill, JH, 2019)
"Three-year OS was 91."	1.51	Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. ( Ahmed, S; Aleman, BMP; Andraos, TY; Balogh, A; Binkley, MS; Brady, JL; Bratman, SV; Chau, K; Chelius, M; Choi, SH; Constine, LS; Dabaja, B; Eich, HT; El-Galaly, TC; Filippi, AR; Hajj, C; Hardy, S; Hodgson, DC; Hoppe, RT; Jones, M; Kirova, YM; Levis, M; MacManus, M; Mikhaeel, NG; Ng, AK; Oguchi, M; Reinartz, G; Ricardi, U; Suh, CO; Vistisen, AK; Wirth, A; Yahalom, J, 2019)
"Cardiotoxicity is a known risk of anthracycline treatment."	1.48	Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. ( Baech, J; Brown, PN; El-Galaly, TC; Haaber, J; Hansen, SM; Josefsson, P; Juul, MB; Jørgensen, J; Lund, PE; Poulsen, CB; Soegaard, P; Starklint, J; Torp-Pedersen, C, 2018)
"Seventy patients with primary follicular lymphomawere in our hospital were treated with R-CHOP chemotherapy, the ALC/AMC value of peripheral blood was recorded, and the prognosis was assessed by the international prognostic index."	1.48	[ALC/AMC Value and Prognosis in Patients with Primary Follicular Lymphoma Treated with R-CHOP Chemotherapy]. ( Cui, Y; Shi, P, 2018)
"He was diagnosed with follicular lymphoma (Ann Arbor stage IVA) and PNP-related BO."	1.46	Achievement of the longest survival of paraneoplastic pemphigus with bronchiolitis obliterans associated with follicular lymphoma using R-CHOP chemotherapy. ( Hashimoto, T; Imamura, S; Ishii, N; Kamiya, K; Kinoshita, K; Lee, S; Yamauchi, T, 2017)
" All patients experienced at least one adverse event during induction, most commonly infusion-related reactions (58%), the majority of which were grade 1/2."	1.46	Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. ( Díaz, MG; Dreyling, M; Dyer, MJ; Grigg, A; Knapp, A; Lei, G; Marlton, P; Rule, S; Wassner-Fritsch, E, 2017)
"The optimal initial therapy of follicular lymphoma (FL) remains unclear."	1.43	Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. ( Ahmed, M; Cheah, CY; Chihara, D; Davis, RE; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Lee, H; Nastoupil, LJ; Neelapu, SS; Oki, Y; Phansalkar, K; Rodriguez, MA; Romaguera, JE; Samaniego, F; Turturro, F; Wang, ML; Westin, JR, 2016)
" These patients may benefit from rituximab combined with intensive chemotherapy."	1.42	[Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement]. ( Li, H; Li, Z; Liu, H; Liu, W; Lü, R; Qiu, L; Xiong, W; Yi, S; Zou, D, 2015)
"Follicular lymphoma is a clinically and genetically heterogeneous disease, but the prognostic value of somatic mutations has not been systematically assessed."	1.42	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. ( Connors, JM; Dreyling, M; Ducar, M; Ennishi, D; Feller, AC; Gascoyne, RD; Hansmann, ML; Hiddemann, W; Horn, H; Hoster, E; Hother, C; Jurinovic, V; Klapper, W; Kopp, N; Kridel, R; Leich, E; Moccia, AA; Möller, P; Mottok, A; Murakami, M; Neuberg, D; Ott, G; Pastore, A; Pott, C; Rosenwald, A; Sehn, LH; Shulha, HP; Staiger, AM; Stein, H; Sunkavalli, A; Szczepanowski, M; Unterhalt, M; Van Hummelen, P; Weigert, O; Weinstock, DM, 2015)
"Chylothorax is most common on the left side owing to the position of the thoracic duct."	1.42	A rare case of bilateral chylothorax: a diagnostic challenge--follicular lymphoma versus primary effusion lymphoma. ( Mora, M; Patel, V; Podder, S; Sivamurthy, S, 2015)
"Twenty percent of patients with follicular lymphoma (FL) experience progression of disease (POD) within 2 years of initial chemoimmunotherapy."	1.42	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. ( Byrtek, M; Casulo, C; Cerhan, JR; Dawson, KL; Farber, CM; Flowers, CR; Friedberg, JW; Hainsworth, JD; Link, BK; Maurer, MJ; Zelenetz, AD; Zhou, X, 2015)
"Eosinophilic fasciitis is an uncommon scleroderma-like connective tissue disease, usually characterized by symmetrical and painful swelling and induration of the skin and thickened fascia infiltrated with lymphocytes and eosinophils."	1.42	Forearm compartment syndrome as a result of eosinophilic fasciitis: case report. ( Alolabi, B; El Bahtimi, R; Jenkinson, RJ; Koo, K; Lesieur, M; Smilovici, B, 2015)
" Patients with documented HBV reactivation were treated with entecavir at a dosage of 0."	1.40	Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. ( Chang, CS; Chen, PJ; Cheng, AL; Chiu, CF; Hsu, C; Hwang, WL; Kao, WY; Lin, J; Lin, SF; Lin, SJ; Liu, TW; Tien, HF; Tsou, HH; Wang, MC; Yao, M, 2014)
"Radiation therapy of follicular lymphoma has showed consistent results, which demonstrated by 100% of 5-year tumor-specific survival in the whole group, 100% disease-free survival in patients with stage II, the lack of recurrence in the irradiation fields."	1.39	[Current technologies in radiotherapy for non-Hodgkin lymphomas]. ( Vinogradova, IuN, 2013)
"Primary intestinal follicular lymphoma affects predominantly elderly patients and has a female predilection."	1.38	[Clinicopathologic analysis of intestinal follicular lymphoma first presenting with gastrointestinal symptoms]. ( Chen, GY; Jin, Y; Wei, XJ; Xie, JL; Zhang, SH; Zhang, YN; Zheng, XD; Zheng, YY; Zhou, XG; Zhu, H, 2012)
" All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations."	1.37	Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma. ( Dogan, A; Galardy, PJ; Khan, SP; Kumar, R; Rodriguez, V, 2011)
"Primary breast lymphoma is a rare disease entity."	1.37	[Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases]. ( Fu, L; Fu, XL; Jin, ZJ; Lang, RG; Liu, FF; Lü, AJ; Wang, XF; Wang, Y; Yang, H, 2011)
"Furthermore, accumulation of MCs in follicular lymphoma (FL) correlates with unfavourable prognosis after immunochemotherapy."	1.36	Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy. ( Bono, P; Jantunen, E; Karjalainen-Lindsberg, ML; Kosma, VM; Leppä, S; Taskinen, M, 2010)
"Waldenström macroglobulinemia is LPL."	1.36	[Clinicopathologic features of lymphoplasmacytic lymphoma]. ( Fang, LH; Li, ZQ; Liu, EB; Qiu, LG; Sun, FJ; Sun, Q; Yang, QY; Zhang, PH, 2010)
"The prognosis and management of acute exacerbations of hepatitis-B in patients with lymphoma after chemotherapy in combination with rituximab remain unclear."	1.36	Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. ( Chen, ZH; Dong, M; Li, X; Lin, Q; Ma, XK; Wei, L; Wen, JY; Wu, XY, 2010)
"Prednisone 50 mg was administered every other day orally for thirty days and then tapered over the next thirty days."	1.35	Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate. ( Bertino, JR; Gharibo, M; Levitt, MJ; Rubin, A; Schaar, D; Strair, R, 2009)
"Follicular lymphoma is the second most common lymphoma throughout the world."	1.35	Meningeal relapse by follicular lymphoma as a single mass. ( Fernández Zubillaga, A; González-Barón, M; Moreno García, V; Redondo, A, 2008)
"Nocardial brain abscess is a rare but severe complication in patients with malignancy."	1.35	Nocardia exalbida brain abscess in a patient with follicular lymphoma. ( Kim, SW; Kobayashi, Y; Maruyama, D; Mikami, Y; Ono, M; Shibata, T; Tobinai, K; Watanabe, T, 2008)
"Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphomas (NHL), but the dosing regimen currently used should be optimized."	1.35	Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. ( Cartron, G; Girard, P; Hénin, E; Paintaud, G; Ternant, D; Tod, M, 2009)
"This report concerns a rare case of follicular lymphoma with features suggestive of primary hepatic lymphoma."	1.34	Primary hepatic follicular lymphoma : a case report and discussion of chemotherapy and favorable outcomes. ( Gomyo, H; Kagami, Y; Kamiya, Y; Kato, H; Kawase, T; Morishima, Y; Nakamura, S; Ogura, M; Ohshiro, A; Oyama, T; Taji, H, 2007)
"Histological, we mainly notified follicular lymphoma constituted of small cells 50%, followed by mixed follicular and large cells lymphomas with respectively 27."	1.34	[Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience]. ( Koffi, G; Kouakou, B; Ndathz, E; Ndiaye, FS; Sangare, A; Sanogo, I, 2007)
"The histopathological study revealed a follicular lymphoma."	1.33	[Medullary compression revealing the presence of a follicular lymphoma: a case report]. ( Bahri Zouari, I; Charfi, S; Daoud, J; Gouiaa, N; Khabir, A; Sellami Boudawara, T; Toumi, N, 2006)
"Patients with follicular lymphoma (FL) in advanced stages are currently deemed incurable with standard treatments."	1.33	Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. ( Arenillas, L; Balaguer, O; Bosch, F; Campo, E; Colomo, L; Ferrer, A; Giné, E; López-Guillermo, A; Montoto, S; Montserrat, E; Muntañola, A; Plancarte, F; Villamor, N, 2006)
"The natural history of follicular lymphoma is believed not to have changed over the last 30 years."	1.33	New treatment options have changed the survival of patients with follicular lymphoma. ( Fisher, RI; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Unger, JM, 2005)
" Following an uncomplicated pregnancy, a healthy child was born at full term and careful haematological and immunological monitoring has revealed no adverse effects resulting from exposure to rituximab."	1.32	Safety of rituximab therapy during the first trimester of pregnancy: a case history. ( Elinder, G; Kimby, E; Sverrisdottir, A, 2004)
"However complicating classical Hodgkin lymphoma (CHL) was noted inside the lesion."	1.32	Composite lymphoma arising in the parotid gland: a case report. ( Abe, M; Kuroda, M; Mizoguchi, Y; Nishio, T; Saito, S; Sakurai, K; Urano, M, 2004)
"Grade 3 follicular lymphoma (FL3) is thought to have an aggressive clinical course."	1.32	A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. ( Aoun, P; Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Greiner, TC; Hans, CP; Hock, LM; Lynch, JC; Vose, JM; Weisenburger, DD, 2003)
" This study also describes the application of the ELISA method to a pharmacokinetic study in a homogeneous group of patients with follicular lymphoma who received 4 weekly doses of MAb at the standard dose of 375 mg/m2 as consolidation of chemotherapy."	1.31	Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. ( Arcaini, L; Astori, C; Avanzini, MA; Iacona, I; Lazzarino, M; Lunghi, F; Morra, E; Orlandi, E; Regazzi, MB; Rupolo, M; Zagonel, V, 2000)
"Primary follicular lymphoma of the testis in childhood is extremely rare."	1.31	Primary follicular large cell lymphoma of the testis in a child. ( Abruzzo, LV; Eskenazi, AE; Lu, D; Medeiros, LJ, 2001)
"The clinical course of follicular lymphoma (FL) is well known."	1.31	Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy. ( Al-Salman, J; Boonswang, P; Salib, H, 2001)
" The IFN dosage was 5 x 10(6) U three times weekly for 18 months."	1.30	Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. ( Cole, BF; Gelber, RD; Gisselbrecht, C; Goldhirsch, A; Lepage, E; Reyes, F; Sebban, C; Solal-Céligny, P; Sugano, D; Tendler, C, 1998)
"We report a case of fulminant myelofibrosis after administration of fludarabine in a patient diagnosed as having refractory low-grade lymphoma, progressing fatally."	1.30	Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma. ( Azaceta, G; Gutierrez, M; Palomera, L; Soria, J; Varo, MJ, 1998)
"Management of follicular lymphoma after chemotherapy failure has been controversial and has ranged from watchful waiting to high-dose chemotherapy."	1.30	Salvage central lymphatic irradiation in follicular lymphomas following failure of chemotherapy: a feasibility study. ( Blanco, AI; Cabanillas, F; Cox, JD; Ha, CS; Tucker, SL, 1999)
"In patients with previously untreated advanced follicular lymphoma, trilineage hematopoietic engraftment was compared in two sequential trials of induction therapy (standard dose cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP] without growth factors or dose intensification CHOP supported by granulocyte colony-stimulating factor [G-CSF ]) followed by identical myeloablative therapy and autologous stem cell support."	1.30	Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. ( Anderson, K; Fisher, DC; Freedman, A; Gribben, J; Kroon, M; Kuhlman, C; Mauch, P; Nadler, L; Neuberg, D; Rhuda, C; Ritz, J; Robertson, M; Schlossman, R; Soiffer, R, 1997)
"Fifty-six patients with malignant lymphoma of aggressive histologic type (51 large cell, three diffuse undifferentiated, and two nodular mixed) were treated with three non-cross-resistant combination chemotherapy regimens that were introduced sequentially according to the response to therapy."	1.27	Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. ( Bodey, GP; Burgess, MA; Cabanillas, F; Freireich, EJ, 1983)
"Low-grade malignant lymphomas are treated best with conventional doses of an alkylating agent."	1.26	[Chemotherapy in non-Hodgkin's lymphomas (author's transl)]. ( Schmidt, CG, 1977)

Research

Studies (381)

Authors

Clinical Trials (31)

Trial Overview

Trial Outcomes

Objective Response (Confirmed and Unconfirmed Complete and Partial Responses)

Timeframe	Studies, this research(%)	All Research%
pre-1990	20 (5.25)	18.7374
1990's	36 (9.45)	18.2507
2000's	124 (32.55)	29.6817
2010's	156 (40.94)	24.3611
2020's	45 (11.81)	2.80

Authors	Studies
Desai, SH	1
LaPlant, B	2
Macon, WR	2
King, RL	1
Wang, Y	4
Inwards, DJ	3
Micallef, I	1
Johnston, PB	2
Porrata, LF	2
Ansell, SM	3
Habermann, TM	8
Witzig, TE	4
Nowakowski, GS	4
Burke, GAA	1
Minard-Colin, V	2
Aupérin, A	1
Alexander, S	1
Pillon, M	1
Delgado, R	1
Zsíros, J	1
Uyttebroeck, A	1
Dartigues, P	1
Miles, RR	1
Kazanowska, B	1
Chiang, AK	1
Haouy, S	2
Bollard, CM	1
Csoka, M	1
Wheatley, K	1
Barkauskas, DA	1
Adamson, PC	1
Vassal, G	1
Patte, C	1
Gross, TG	1
Leslie, LA	1
Luminari, S	8
Manni, M	3
Galimberti, S	3
Versari, A	2
Tucci, A	5
Boccomini, C	3
Farina, L	1
Olivieri, J	1
Marcheselli, L	7
Guerra, L	1
Ferrero, S	2
Arcaini, L	8
Cavallo, F	1
Kovalchuk, S	2
Skrypets, T	2
Del Giudice, I	1
Chauvie, S	1
Patti, C	2
Stelitano, C	6
Ricci, F	1
Pinto, A	1
Margiotta Casaluci, G	1
Zilioli, VR	1
Merli, A	1
Ladetto, M	3
Bolis, S	2
Pavone, V	1
Chiarenza, A	3
Arcari, A	2
Anastasia, A	2
Dondi, A	4
Mannina, D	2
Federico, M	9
Zhou, S	2
Qi, X	1
Yang, F	1
Maurer, MJ	3
Wang, ML	2
Cahill, KE	1
Smith, SM	3
Miyazaki, K	2
Pavlovsky, M	1
Cubero, D	1
Agreda-Vásquez, GP	1
Enrico, A	1
Mela-Osorio, MJ	1
San Sebastián, JA	1
Fogliatto, L	1
Ovilla, R	1
Avendano, O	1
Machnicki, G	1
Barreyro, P	1
Trufelli, D	1
Villanova, P	1
Ngu, H	1
Takiar, R	1
Phillips, T	1
Okosun, J	1
Sehn, LH	4
Claustre, G	1
Boulanger, C	1
Maloisel, F	1
Etienne-Selloum, N	1
Fornecker, LM	1
Durot, E	1
Slimano, F	1
Graff, V	1
Xie, C	1
Li, R	1
Huang, X	1
Chihara, D	2
Flowers, CR	9
Martínez-Laperche, C	1
Sanz-Villanueva, L	1
Díaz Crespo, FJ	1
Muñiz, P	1
Martín Rojas, R	1
Carbonell, D	1
Chicano, M	1
Suárez-González, J	1
Menárguez, J	1
Kwon, M	1
Diez Martín, JL	1
Buño, I	1
Bastos Oreiro, M	1
Zduniak, A	1
Lévêque, E	1
Perdrix, A	1
Etancelin, P	1
Ménard, AL	1
Lenain, P	1
Contentin, N	1
Pépin, LF	1
Leprêtre, S	1
Lemasle, E	1
Lanic, H	1
Stamatoullas-Bastard, A	1
Kammoun-Quique, L	1
Tilly, H	8
Bauer, F	1
Jardin, F	2
Camus, V	1
Rodríguez-Sevilla, JJ	1
Fernández-Rodríguez, C	1
Bento, L	1
Diez-Feijóo, R	1
Pinzón, S	1
Gibert, J	1
Fernández-Ibarrondo, L	1
Lafuente, M	1
Ferrer, A	2
Sánchez-González, B	1
Gimeno, E	1
Sainz, J	1
Ramos, R	1
García, JF	1
Colomo, L	2
Bellosillo, B	1
Gutiérrez, A	1
Salar, A	2
Osanai, S	1
Oshima, S	1
Itoi, S	1
Kato, Y	2
Ryuzaki, M	1
Izuka, Y	1
Tanaka, N	1
Ishiyama, M	1
Shinohara, A	1
Yoshinaga, K	1
Shiseki, M	1
Onizuka, H	1
Nagashima, Y	1
Tanaka, J	1
Dourthe, ME	1
Simonin, M	1
Rigaud, C	1
Montravers, F	1
Ducou Le Pointe, H	1
Garnier, N	1
Jo Molina, T	1
Boudjemaa, S	1
Leblanc, T	1
Landman-Parker, J	1
Nizzoli, ME	1
Ghiggi, C	1
Pulsoni, A	7
Musuraca, G	2
Merli, M	1
Califano, C	1
Bari, A	3
Massaia, M	1
Conconi, A	1
Musto, P	2
Perrone, T	1
Re, F	1
Gini, G	1
Capponi, M	1
Vitolo, U	8
Usai, SV	1
Stefani, PM	1
Ballerini, F	1
Liberati, AM	1
Pennese, E	1
Pastore, D	1
Catellani, H	1
Burack, WR	1
Li, H	5
Adlowitz, D	1
Spence, JM	1
Rimsza, LM	3
Shadman, M	2
Spier, CM	2
Kaminski, MS	3
Leonard, JP	4
Leblanc, ML	1
Friedberg, JW	9
Nastoupil, LJ	5
Hess, G	2
Pavlovsky, MA	1
Danielewicz, I	1
Freeman, J	1
García-Sancho, AM	1
Glazunova, V	1
Grigg, A	2
Hou, JZ	1
Janssens, A	1
Kim, SJ	2
Masliak, Z	1
McKay, P	1
Merli, F	5
Munakata, W	1
Nagai, H	1
Özcan, M	1
Preis, M	1
Wang, T	1
Rowe, M	1
Tamegnon, M	1
Qin, R	1
Henninger, T	1
Curtis, M	1
Caces, DB	1
Thieblemont, C	2
Salles, G	14
Cameron Smail, R	1
O'Neill, JH	1
Andresen, D	1
Walewski, J	3
Paszkiewicz-Kozik, E	2
Michalski, W	1
Rymkiewicz, G	1
Szpila, T	1
Butrym, A	1
Giza, A	1
Zaucha, JM	1
Kalinka-Warzocha, E	1
Wieczorkiewicz, A	1
Zimowska-Curyło, D	1
Knopińska-Posłuszny, W	1
Tyczyńska, A	1
Romejko-Jarosińska, J	1
Dąbrowska-Iwanicka, A	1
Gruszecka, B	1
Jamrozek-Jedlińska, M	1
Borawska, A	1
Hołda, W	1
Porowska, A	1
Romanowicz, A	1
Hellmann, A	1
Stella-Hołowiecka, B	1
Deptała, A	1
Jurczak, W	1
Hara, T	2
Suzuki, R	1
Ohno, A	1
Yamakawa, K	1
Yamagishi, Y	1
Sugiyama, Y	1
Sobajima, T	1
Yamada, R	1
Matsumoto, R	1
Ikeda, Y	2
Murayama, M	1
Tsurumi, H	2
Bravo-Perez, C	1
Pajares, I	1
Muiña, B	1
Escobar, H	1
Amigo, ML	1
Garcia-Malo, MD	1
Garcia, J	1
Rodriguez-Pinilla, SM	1
Piris, MA	2
Ortuño, FJ	1
Batlevi, CL	1
Sha, F	1
Alperovich, A	1
Ni, A	1
Smith, K	1
Ying, Z	1
Gerecitano, JF	1
Hamlin, PA	1
Horwitz, SM	1
Joffe, E	1
Kumar, A	1
Matasar, MJ	1
Moskowitz, AJ	1
Moskowitz, CH	1
Noy, A	1
Owens, C	1
Palomba, LM	1
Straus, D	1
von Keudell, G	1
Zelenetz, AD	3
Seshan, VE	1
Younes, A	3
Strati, P	1
Ahmed, MA	1
Feng, L	3
Hagemeister, FB	7
Fayad, LE	5
Rodriguez, MA	6
Samaniego, F	4
Wang, M	1
Westin, JR	3
Lee, HJ	1
Iyer, SP	1
Parmar, S	1
Ahmed, S	2
Nair, R	1
Steiner, RE	1
Noorani, M	1
Davis, RE	2
Fowler, NH	3
Neelapu, SS	3
Ziemba, JB	1
Wolf, Z	1
Weinstock, M	1
Asakrah, S	1
López-Díaz de Cerio, A	1
García-Muñoz, R	1
Pena, E	1
Panizo, Á	1
Feliu, J	1
Giraldo, P	1
Rodríguez-Calvillo, M	1
Martínez-Calle, N	1
Grande, C	1
Olave, MT	1
Andrade-Campos, M	1
Bandrés, E	1
Núñez-Córdoba, JM	1
Inogés, S	1
Panizo, C	1
Sortais, C	1
Lok, A	1
Tessoulin, B	1
Gastinne, T	1
Mahé, B	1
Dubruille, V	1
Blin, N	1
Touzeau, C	1
Moreau, A	1
Bossard, C	1
Peterlin, P	1
Garnier, A	1
Guillaume, T	1
Le Bourgeois, A	1
Chevallier, P	1
Moreau, P	1
Leux, C	1
Le Gouill, S	2
Owens, M	1
Choe, L	1
Rivera, JE	1
Avila, JD	1
Nesterova, E	1
Tanaschuk, E	1
Abdurakhmanov, D	1
Gemdzhian, E	1
Kravchenko, S	1
Mangasarova, Y	1
Krasilnikova, I	1
Bagova, M	1
Ikeda, T	3
Fujiwara, SI	2
Nakajima, H	1
Kawaguchi, SI	1
Toda, Y	2
Ito, S	3
Ochi, S	1
Nagayama, T	1
Mashima, K	2
Umino, K	2
Minakata, D	2
Nakano, H	2
Morita, K	1
Yamasaki, R	2
Kawasaki, Y	2
Ashizawa, M	2
Yamamoto, C	2
Hatano, K	2
Sato, K	2
Oh, I	2
Ohmine, K	2
Muroi, K	2
Kanda, Y	2
Lucijanic, M	1
Jaksic, O	1
Hengeveld, PJ	1
de Jongh, E	1
Westerweel, PE	1
Levin, MD	1
Pouyiourou, M	1
Meyer, A	1
Stroux, A	1
Viardot, A	2
La Rosée, P	1
Maschmeyer, G	3
Kämpfe, D	1
Kahl, C	1
Vucinic, V	1
Monecke, A	1
Hirt, C	2
Weber, T	1
Meissner, J	1
Witzens-Harig, M	6
Böttcher, S	1
Schmalenberg, H	1
Marks, R	1
Prange-Krex, G	1
Kroschinsky, F	1
Hauf, E	1
Keller, U	1
Koch, K	1
Klapper, W	5
Herold, M	5
Scholz, CW	1
Cerchione, C	2
Nappi, D	2
Lucchesi, A	1
Cimmino, I	1
Pane, F	1
De Renzo, A	2
Martinelli, G	1
Alig, S	3
Jurinovic, V	5
Shahrokh Esfahani, M	1
Haebe, S	2
Passerini, V	1
Hellmuth, JC	2
Gaitzsch, E	1
Keay, W	1
Tahiri, N	1
Zoellner, A	1
Rosenwald, A	3
Stein, H	3
Feller, A	1
Ott, G	3
Staiger, AM	2
Horn, H	3
Hansmann, ML	2
Pott, C	2
Unterhalt, M	8
Schmidt, C	3
Dreyling, M	8
Alizadeh, AA	2
Hiddemann, W	12
Hoster, E	7
Weigert, O	6
Zhou, Y	1
Qin, Y	1
He, X	2
Liu, P	1
Yang, J	1
Zhou, L	1
Gui, L	1
Yang, S	1
Zhang, C	1
Shi, Y	1
Chin, CK	1
Lim, KJ	1
Lewis, K	1
Jain, P	1
Qing, Y	1
Cheah, CY	2
Seymour, JF	6
Ritchie, D	1
Burbury, K	1
Tam, CS	1
Dickinson, MJ	1
Mozas, P	1
Rivero, A	1
Rivas-Delgado, A	1
Fabregat, A	1
Piñeyroa, JA	1
Correa, JG	1
Nadeu, F	1
Oliver, A	1
Bataller, A	1
Giné, E	3
Delgado, J	1
Villamor, N	2
Cibeira, MT	1
Fernández de Larrea, C	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL[NCT01516567]	Phase 2	47 participants (Actual)	Interventional	2012-04-01	Active, not recruiting
A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.[NCT02063685]	Phase 3	807 participants (Actual)	Interventional	2012-07-31	Completed
Phase III Multicentric IIL Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Treatment of Patients With Stage II-IV Follicular Lymphoma[NCT00774826]	Phase 3	534 participants (Actual)	Interventional	2005-12-31	Active, not recruiting
A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas[NCT00006721]	Phase 3	571 participants (Actual)	Interventional	2001-03-31	Active, not recruiting
A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101[NCT01332968]	Phase 3	1,401 participants (Actual)	Interventional	2011-07-06	Completed
A Phase Ib/II Study of Escalating Doses of Revlimid in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma[NCT01393756]	Phase 2	80 participants (Actual)	Interventional	2010-12-31	Completed
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry[NCT04587388]		500 participants (Anticipated)	Observational [Patient Registry]	2019-05-22	Recruiting
An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma[NCT00825149]	Phase 1	137 participants (Actual)	Interventional	2009-02-28	Completed
Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents[NCT03816683]		229 participants (Actual)	Observational	2019-04-01	Active, not recruiting
Early Detection of Cardiac Toxicity in Childhood Cancer Survivors[NCT03038997]		42 participants (Actual)	Observational	2014-11-30	Terminated (stopped due to IRB approval expired)
A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma[NCT00017290]	Phase 3	0 participants	Interventional	2000-11-30	Active, not recruiting
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma.[NCT00715208]	Phase 2	55 participants (Actual)	Interventional	2008-09-30	Completed
Phase II of Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Patients With Relapsed or Refractory Follicular Lymphoma[NCT00366275]	Phase 2	64 participants (Actual)	Interventional	2002-01-31	Completed
Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas[NCT00991211]	Phase 3	549 participants (Actual)	Interventional	2004-01-31	Completed
A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas[NCT00634179]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2008-02-29	Completed
Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response[NCT04508647]	Phase 2	4 participants (Actual)	Interventional	2020-11-23	Completed
Short Chemo Radiotherapy in Follicular Lymphoma Trial of 90Y Ibritumomab Tiuxetan (ZevalinTM) as Therapy for First and Second Relapse in Follicular Lymphoma[NCT00637832]	Phase 2	1 participants (Actual)	Interventional	2008-04-01	Terminated (stopped due to no information)
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma[NCT02008006]	Phase 2	21 participants (Actual)	Interventional	2014-07-09	Terminated (stopped due to Insufficient recruitment and unavailability of the treatment)
Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) in Remission Induction and Maintenance Treatment of Relapsed Follicular Non-Hodgkin's Lymphoma: A Phase III Randomized Clinical Trial - Intergroup Collaborative Study[NCT00004179]	Phase 3	475 participants (Actual)	Interventional	1999-05-31	Completed
Phase II Multicenter Study of Cyclophosphamide, Vincristine, and Prednisone (CVP) Followed by Iodine-131 Anti-B1 Antibody for Patients With Untreated Low-grade Non-Hodgkin's Lymphoma (NHL).[NCT01663714]	Phase 2	30 participants (Actual)	Interventional	2000-02-29	Completed
National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation[NCT02340936]	Phase 1/Phase 2	53 participants (Actual)	Interventional	2011-01-31	Completed
Therapy of Nodal Follicular Lymphoma (WHO Grade 1/2) in Clinical Stage I/II Using Response Adapted Involved Site Radiotherapy in Combination With Gazyvaro[NCT03341520]	Phase 2	89 participants (Actual)	Interventional	2018-04-24	Active, not recruiting
A Multi-Centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone, and Rituximab (BCVP-R) for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma Requiring Systemic First-[NCT00428142]	Phase 2	95 participants (Actual)	Interventional	2007-05-01	Completed
An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With CHOP, in Patients With Previously Untreated Follicular Lymphoma (FL).[NCT00494780]	Phase 2	59 participants (Actual)	Interventional	2007-06-30	Completed
High Tumor Burden Follicular Lymphoma: Impact of [18F]-FDG Positron Emission Tomography (PET) in the Assessment of Treatment Response[NCT00915096]		121 participants (Actual)	Observational	2007-09-18	Completed
A Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas[NCT00003784]	Phase 2	102 participants (Actual)	Interventional	1999-05-31	Completed
Exploring Patient Engagement Patterns and Participation Trends in Mantle Cell Lymphoma Clinical Trials[NCT06049472]		500 participants (Anticipated)	Observational	2024-10-31	Not yet recruiting
"MIRO (Molecularly Oriented Immuno - Radio -Therapy): Multicenter Phase II Study for the Treatment of the Molecular Basis of Stage I / II Follicular Lymphoma With Local Radiotherapy With / Without Ofatumumab"[NCT02710643]	Phase 2	110 participants (Actual)	Interventional	2014-10-31	Completed
FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden[NCT00136552]	Phase 3	360 participants	Interventional	2000-05-31	Completed
Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib (EPOCH-R-B) Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics[NCT00114738]	Phase 2	53 participants (Actual)	Interventional	2005-06-15	Completed
Randomized Study for Patients With Follicular Lymphoma Needing Treatment[NCT00140569]	Phase 3	400 participants	Interventional	1994-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow(BM) must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. Partial Response(PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. (NCT00006721)
Timeframe: Assessed 200 days and 365 days after initiation of therapy and then every 6 months until death

Overall Survival at 2 Years

Intervention	participants (Number)
CHOP + Rituximab	224
CHOP + Tositumomab	223

Measured from date of registration to date of death due to any cause (NCT00006721)
Timeframe: 0-2 years

Overall Survival at 5 Years

Intervention	percentage of participants (Number)
CHOP + Rituximab	97
CHOP + Tositumomab	93

Measured from date of registration to date of death due to any cause (NCT00006721)
Timeframe: 0-5 years

Progression-free Survival at 2 Years

Intervention	percentage of participants (Number)
CHOP + Rituximab	92
CHOP + Tositumomab	86

Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date (NCT00006721)
Timeframe: 0-2 years

Progression-free Survival at 5 Years

Intervention	percentage of participants (Number)
CHOP + Rituximab	76
CHOP + Tositumomab	80

Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date (NCT00006721)
Timeframe: 0-5 years

Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug

Intervention	percentage of participants (Number)
CHOP + Rituximab	60
CHOP + Tositumomab	66

Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 2.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal (NCT00006721)
Timeframe: Patients were assessed for adverse events at end of cycle 1-6 of CHOP or R-CHOP, the end of cycle 1-6 of CHOP and once 2 weeks after the completion of I-131 treatment. For either arm, once 3 months after removal from protocol treatment

Disease-Free Survival (Follicular Lymphoma Population)

Intervention	Participants (Number)
	ARDS	Abdominal pain/cramping	Allergic reaction	Anemia	Anorexia	Anxiety/agitation	Arrhythmia, NOS	Arthralgia	Arthritis	Ascites (non-malignant)	Ataxia (incoordination)	Bone pain	Cardiac ischemia/infarction	Cardiovascular-other	Cataract	Catheter related infection	Cerebrovascular ischemia	Chest pain,not cardio or pleur	Constipation/bowel obstruction	Cough	Dehydration	Delusions	Depression	Diarrhea without colostomy	Dizziness/light headedness	Double vision	Dyspepsia/heartburn	Dyspnea	Edema	Esophagitis/dysphagia	Fatigue/malaise/lethargy	Febrile neutropenia	Fever without neutropenia	Fever, NOS	Flu-like symptoms-other	Gastric ulcer	Gynecomastia	Headache	Hematologic-other	Hyperglycemia	Hypertension	Hyperuricemia	Hypoalbuminemia	Hypokalemia	Hyponatremia	Hypophosphatemia	Hypotension	Hypoxia	Ileus	Infection w/o 3-4 neutropenia	Infection with 3-4 neutropenia	Infection, unk ANC	Insomnia	Invol. movement/restlessness	Joint,muscle,bone-other	LVEF decrease/CHF	Leukopenia	Lymphopenia	Menses changes	Muscle weakness (not neuro)	Myalgia	Myalgia/arthralgia, NOS	Nausea
CHOP + Rituximab	0	4	9	7	3	1	1	3	0	0	2	2	1	1	1	2	1	4	5	0	5	0	0	3	0	1	1	4	0	1	11	42	1	1	1	0	0	2	0	10	1	1	1	2	4	1	2	1	1	4	14	4	2	1	0	1	104	64	2	2	2	2	6
CHOP + Tositumomab	1	3	1	8	2	3	0	1	1	1	1	0	1	1	0	0	0	0	4	1	1	1	2	3	1	0	0	4	2	1	9	26	0	0	0	1	1	1	3	3	1	0	0	2	1	0	1	0	0	5	9	3	1	0	1	0	102	68	2	3	3	3	10
CHOP Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	0	0	0	0	1

Disease-free survival in the follicular lymphoma population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma (RRCML). Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Reported is the percentage of participants with event. (NCT01332968)
Timeframe: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)

Disease-Free Survival (Overall Study Population)

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	27.9
Obinutuzumab+Chemotherapy	26.3

Disease-free survival in the overall study population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Reported is the percentage of participants with event. (NCT01332968)
Timeframe: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)

Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	14.9
Obinutuzumab+Chemotherapy	11.2

DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as >/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. (NCT01332968)
Timeframe: From first occurrence of documented CR or PR to data cut-off (up to approximately 5 years and 2 months)

Duration of Response (DOR) (Overall Study Population), Investigator-Assessed

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	39.3
Obinutuzumab+Chemotherapy	33.3

Event-Free Survival (Follicular Lymphoma Population)

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	25.5
Obinutuzumab+Chemotherapy	18.7

Event-free survival in the follicular lymphoma population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with an event. (NCT01332968)
Timeframe: Baseline up to 10 years

Event-Free Survival (Overall Study Population)

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	42.9
Obinutuzumab+Chemotherapy	35.8

Event-free survival in the overall study population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event. (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 5 years and 2 months)

Overall Survival (Follicular Lymphoma Population)

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	30.6
Obinutuzumab+Chemotherapy	22.6

Overall survival in the follicular lymphoma population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event. (NCT01332968)
Timeframe: Baseline up to 10 years

Overall Survival (Overall Study Population)

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	14.3
Obinutuzumab+Chemotherapy	12.6

Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event. (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 5 years and 2 months)

Percentage of Participants With Adverse Events

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	10.2
Obinutuzumab+Chemotherapy	8.4

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT01332968)
Timeframe: Baseline up to 10 years

Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed

Intervention	percentage of participants (Number)
Rituximab+Chemotherapy	99.6
Obinutuzumab+Chemotherapy	99.9

Progression-free survival in the participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. In the first 170 patients with follicular lymphoma, an FDG-PET was mandatory where a PET scanner was available. (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 5 years and 2 months)

Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	23.5
Obinutuzumab+Chemotherapy	18.0

Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 5 years and 2 months)

Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	24.6
Obinutuzumab+Chemotherapy	18.4

Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI). (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 4 years and 7 months)

Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	24.0
Obinutuzumab+Chemotherapy	16.8

Progression-Free Survival in the Overall Study Population, Investigator-Assessed

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	40.6
Obinutuzumab+Chemotherapy	34.3

Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 5 years and 2 months)

Time to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population)

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	41.5
Obinutuzumab+Chemotherapy	34.8

Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event. (NCT01332968)
Timeframe: Baseline up to 10 years

Time to Next Anti-Lymphoma Treatment (Overall Study Population)

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	34.8
Obinutuzumab+Chemotherapy	26.6

Change From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)

Intervention	percentage of participants with event (Number)
Rituximab+Chemotherapy	21.6
Obinutuzumab+Chemotherapy	15.7

FACT-G consists of the following 4 FACT-Lym sub-questionnaires: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24) and Functional Well-being (range: 0-28). Higher scores indicate better outcomes. A positive change from baseline indicates improvement. Maint = Maintenance period. (NCT01332968)
Timeframe: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Follow Up Phase

Intervention	units on a scale (Mean)
	Physical Well-being (PW), Baseline	PW Change, Cycle 3, Day 1	PW Change, End Induction	PW Change, Maint Month 2	PW Change, Maint Month 12	PW Change, End Maint	Social/Family Well-being , Baseline	S/FW Change, Cycle 3 Day 1	S/FW Change, End Induction	S/FW Change, Maint Month 2	S/FW Change, Maint Month 12	S/FW Change, End Maint	Emotional Well-being (EW), Baseline	EW Change, Cycle 3 Day 1	EW Change, End Induction	EW Change, Maint Month 2	EW Change, Maint Month 12	EW Change, End Maint	Functional Well-being (FW), Baseline	FW Change, Cycle 3 Day 1	FW Change, End Induction	FW Change, Maint Month 2	FW Change, Maint Month 12	FW Change, End Maint
Obinutuzumab+Chemotherapy	23.14	-0.21	0.56	1.42	1.34	1.33	23.28	-0.67	-0.56	-0.67	-0.97	-0.71	17.87	1.35	1.14	1.49	1.46	1.49	18.76	-0.07	0.93	1.25	1.65	1.72
Rituximab+Chemotherapy	23.36	-0.91	-0.06	0.83	1.14	0.88	22.84	-0.52	-0.46	-0.39	-0.61	-0.93	17.64	1.49	1.16	1.77	1.45	1.43	18.66	-0.30	0.44	1.04	1.84	1.40

The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs in data categories. Completion includes completion visit and early termination visit. (NCT01332968)
Timeframe: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 after Day 1 of last induction cycle, Follow-up: every year for up to data cut-off (up to 5 years and 2 months)

Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase

Intervention	units on a scale (Mean)
	Change Baseline, Follow-Up Month 36	Change Baseline, Follow-Up Month 48
Obinutuzumab+Chemotherapy	0.06	0.06
Rituximab+Chemotherapy	0.05	0.05

The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Completion (Compl) includes completion visit and early termination visit. Maintenance/Observation is indicated as Maint/Obs. (NCT01332968)
Timeframe: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)

Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase

Intervention	units on a scale (Mean)
	Baseline Induction	Change Baseline, Cycle 3 Day 1	Change Baseline, Induction Compl	Change Baseline, Maint/Obs Month 2	Change from Baseline, Maint/Obs Month 12
Rituximab+Chemotherapy	0.80	0.03	0.04	0.05	0.00

The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Completion (Compl) includes completion visit and early termination visit. Maintenance/Observation is indicated as Maint/Obs. (NCT01332968)
Timeframe: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)

Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Maintenance/Observation Phase

Intervention	units on a scale (Mean)
	Baseline Induction	Change Baseline, Cycle 3 Day 1	Change Baseline, Induction Compl	Change Baseline, Maint/Obs Month 2	Change from Baseline, Maint/Obs Month 12	Change Baseline, Maint/Obs Completion
Obinutuzumab+Chemotherapy	0.81	0.03	0.03	0.06	-0.20	-0.10

The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1 Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs. Completion includes completion visit and early termination visit. (NCT01332968)
Timeframe: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)

Change From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)

Intervention	units on a scale (Mean)
	Change Baseline, Maint/Obs Month 2	Change Baseline, Maint/Obs Month 12	Change Baseline, Maint/Obs Completion
Obinutuzumab+Chemotherapy	0.04	0.06	0.05
Rituximab+Chemotherapy	0.04	0.06	0.03

The FACT-Lym Individual Subscale Lymphoma Score for the follicular lymphoma population was derived from the Lymphoma subscale questionnaire (range: 0-60). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. (NCT01332968)
Timeframe: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

Change From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)

Intervention	units on a scale (Mean)
	Lymphoma, Baseline	Lymphoma Change, Cycle 3 Day 1	Lymphoma Change, End Induction	Lymphoma Change, Maint Month 2	Lymphoma Change, Maint Month 12	Lymphoma Change, End Maint
Obinutuzumab+Chemotherapy	45.54	2.71	3.01	4.52	4.27	4.57
Rituximab+Chemotherapy	45.01	2.04	2.99	4.80	4.93	4.31

The FACT-Lym TOI Score for the follicular lymphoma population was derived from the following 3 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym TOI Score is the sum of the 3 individual subscales (range 0-116). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. (NCT01332968)
Timeframe: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)

Intervention	units on a scale (Mean)
	TOI Score, Baseline	TOI Score Change, Cycle 3 Day 1	TOI Score Change, End Induction	TOI Score Change, Maint M2	TOI Score Change, Maint M12	TOI Score Change, End Maint
Obinutuzumab+Chemotherapy	86.94	2.18	4.57	7.17	7.20	7.44
Rituximab+Chemotherapy	86.61	0.46	2.91	6.22	7.61	6.23

The FACT-Lym Total Score for the follicular lymphoma population was derived from the following 5 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24),Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym Total Score is the sum of all 5 individual subscales (range 0-168). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. (NCT01332968)
Timeframe: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

Complete Response (Follicular Lymphoma Population), Investigator-Assessed

Intervention	units on a scale (Mean)
	Total Score, Baseline	Total Score Change, Cycle 3 Day 1	Total Score Change, End Induction	Total Score Change, Maint Month 2	Total Score Change, Maint Month 12	Total Score Change, End Maint
Obinutuzumab+Chemotherapy	128.42	3.21	5.10	8.13	7.90	8.80
Rituximab+Chemotherapy	127.40	1.98	4.18	8.40	8.87	7.43

Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

Complete Response (Follicular Lymphoma Population), IRC-Assessed

Intervention	percentage of participants with event (Number)
	Without PET	With PET
Obinutuzumab+Chemotherapy	18.6	62.0
Rituximab+Chemotherapy	24.1	56.7

Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

Complete Response (Overall Study Population), Investigator-Assessed

Intervention	percentage of participants with event (Number)
	Without PET	With PET
Obinutuzumab+Chemotherapy	28.5	71.4
Rituximab+Chemotherapy	26.8	59.7

Percentage of participants with complete response in the overall study population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

Complete Response (Overall Study Population), IRC-Assessed

Intervention	percentage of participants with event (Number)
	Without PET	With PET
Obinutuzumab+Chemotherapy	18.4	61.1
Rituximab+Chemotherapy	23.3	57.0

Percentage of participants with complete response in the overall study population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)]

Overall Response (Follicular Lymphoma Population), Investigator-Assessed

Intervention	percentage of participants with event (Number)
	Without PET	With PET
Obinutuzumab+Chemotherapy	27.1	69.5
Rituximab+Chemotherapy	26.3	59.4

Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with and without PET. CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%. Overall Response (OR) = CR + PR. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

Overall Response (Follicular Lymphoma Population), IRC-Assessed

Intervention	percentage of participants with event (Number)
	Without PET	With PET
Obinutuzumab+Chemotherapy	88.2	85.5
Rituximab+Chemotherapy	86.4	81.2

Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%. Overall Response (OR) = CR + PR. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

Overall Response (Overall Study Population), Investigator-Assessed

Intervention	percentage of participants with event (Number)
	Without PET	With PET
Obinutuzumab+Chemotherapy	91.3	88.6
Rituximab+Chemotherapy	88.0	85.2

Overall response in the overall study population was defined as percentage of participants with partial response (PR) or complete response (CR) determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without positron emission tomography (PET). CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%; Overall Response (OR) = CR + PR. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

Overall Response (Overall Study Population), IRC-Assessed

Intervention	percentage of participants with event (Number)
	Without PET	With PET
Obinutuzumab+Chemotherapy	87.3	85.4
Rituximab+Chemotherapy	85.7	81.8

Overall response in the overall study population was defined as percentage of participants with PR or CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%; Overall Response (OR) = CR + PR. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

Duration of Response

Intervention	percentage of participants with event (Number)
	Without PET	With PET
Obinutuzumab+Chemotherapy	89.9	87.2
Rituximab+Chemotherapy	86.7	83.3

"Time (in months) from the first documentation of a response (CR or partial response [PR]) to the date of first documentation of progressive disease or relapse from complete response.~CR is defined as disappearance of all evidence of disease assessed by CT or PET; PR is defined as regression of measurable disease and no new sites assessed by CT or PET according to the revised International Working Group (IWG) Criteria." (NCT00715208)
Timeframe: 2 years

Number of Participants With Overall Response (OR)

Intervention	Months (Median)
VELCADE R-CP	21.9

"OR = Complete Response (CR) + Partial Response (PR)according to the revised International Working Group (IWG) Criteria.~CR is the disappearance of all evidence of disease assessed by CT and PET. PR is the regression of measurable disease and no new sites assessed by CT and PET." (NCT00715208)
Timeframe: 30 weeks

Number of Patients Who Experienced at Least One Serious Adverse Event

Intervention	participants (Number)
VELCADE R-CAP	6
VELCADE R-CP	37

(NCT00715208)
Timeframe: From completion of informed consent through 30 days after the last dose of study drug

Number of Patients With Complete Response (CR)

Intervention	participants (Number)
VELCADE R-CAP	2
VELCADE R-CP	12

Disappearance of all evidence of disease assessed by computed tomography (CT) and PET (position-emission tomography) according to the revised International Working Group (IWG) Criteria. (NCT00715208)
Timeframe: 30 weeks

Percentage of Participants With Progression-free Survival (PFS) at 1 Year

Intervention	participants (Number)
VELCADE R-CAP	1
VELCADE R-CP	13

PFS was defined as the time from the first dose to the date of progressive disease (PD)/relapse or death, whichever comes first. For a participant who had not progressed/relapsed or died, PFS was censored at the last response assessment that was stable disease (failure to attain complete response/partial response or PD or better). (NCT00715208)
Timeframe: Assessed at at the end of Cycle 2, at end of treatment visit, and every 12± 1 weeks for the first year (4 visits) until PD

Progression-free Survival

Intervention	percentage of participants (Number)
VELCADE R-CAP	67
VELCADE R-CP	63

"PFS is calculated according to the Kaplan-Meier estimator. The observation time of each subject is defined as the time from entry into the study until lymphoma progression or death as a result of any cause whichever occurs first.~The 5-year PFS is the estimated cumulative probability of surviving at least 5 years without progression." (NCT00366275)
Timeframe: every 3 months for the first year after autotransplant and every 6 months after the first year of follow up

Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)

Intervention	percent chance of PFS at 5 years (Number)
Immunochemotherapy, in Vivo Purging and Autotransplant	59

INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression. (NCT00634179)
Timeframe: Cycle 1 for MTD, following completion of therapy for CR, up to 24 weeks

An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria

Intervention	mg/m^2 (Number)
MTD of Bortezomib With Vincristine Capped at 1.5 mg	1.62

Response was assessed by computerized tomography (CT) after every 2 cycles of induction therapy, one time at least 4 weeks after completing induction (i.e., prior to maintenance), and then every 3 months while on maintenance therapy. At the conclusion of maintenance therapy, patients underwent one post-treatment scan, with further scans completed at the discretion of the treating physician. Positron emission tomography was permitted but only CT measurements were used to determine response. (NCT00634179)
Timeframe: Following completion of therapy, up to 2 years

Number of Participants With Complete Response Rate (CR) at 8 Weeks Post Single Agent Induction

Intervention	participants (Number)
	Complete Response (CR)	Partial Response (PR)	Overall Response Rate (ORR)
Phase I: Induction	13	6	19
Phase II: Maintenance	19	10	29

"Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.~Patients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib." (NCT04508647)
Timeframe: 8 weeks post induction

Number of Participants With Complete Response Rate (CR) at up to 12 Months Post MONO - Monotherapy: Ublituximab or Combotherapy: Ublituximab + Umbralisib.

"Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake." (NCT04508647)
Timeframe: up to 12 months post induction

Overall Response Rates (ORR) for Number of Participants

"Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Overall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (> 50% improvement) and stable disease (less than 50 % response)" (NCT04508647)
Timeframe: up to 12 months post induction

Nadir Values for Absolute Neutrophil Count (ANC)

Nadir is defined as the lowest laboratory value recorded up to 120 days following the therapeutic dose (or the dosimetric dose for participants who did not receive the therapeutic dose). (NCT01663714)
Timeframe: Up to 120 days following the therapeutic dose (given on Study Day 7, following the dosimetric dose) (or the dosimetric dose for participants who did not receive the therapeutic dose)

Nadir Values for Hemoglobin

Nadir Values for Platelet Count

Nadir Values for WBC Count

Number of Participants (Par.) With Confirmed Response (Complete Response [CR], Complete Response/Unconfirmed [CRu], or Partial Response [PR]), as Assessed by the Investigator

CR: complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. CRu: complete resolution of all disease-related symptoms; residual lymph node mass >1.5 centimeters in the greatest transverse diameter that has regressed by >75%, indeterminate bone marrow, are present. PR: >=50% reduction in the sum of the products of the longest perpendicular diameters of all measurable lesions; no new lesions. Confirmed response required CR, CRu, or PR, which were confirmed by 2 separate response evaluations >=4 weeks apart. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Number of Participants (Par.) With Unconfirmed Response (Complete Response, Complete Response/Unconfirmed, or Partial Response), as Assessed by the Investigator

Par. with response include those with Complete Response (CR: complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease), Complete Response/unconfirmed (CRu: complete resolution of all disease-related symptoms; residual lymph node mass >1.5 centimeters in the greatest transverse diameter that has regressed by >75%, indeterminate bone marrow, are present), or Partial Response (PR: >=50% reduction in the sum of the products of the longest perpendicular diameters of all measurable lesions; no new lesions). (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Number of Participants Who Received Any Supportive Care

Supportive care is defined as interventions that help the participants achieve comfort but do not affect the course of a disease. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Number of Participants With Confirmed Complete Response (CR), as Assessed by the Investigator

CR: complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease, if present before therapy. Confirmed response required CR, which was confirmed by 2 separate response evaluations >=4 weeks apart. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Number of Participants With Unconfirmed Complete Response (CR), as Assessed by the Investigator

CR: complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease, if present before therapy. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Overall Survival

Overall survival is defined as the time from the treatment start date to the date of death from any cause. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Time to Progression of Disease or Death, as Assessed by the Investigator

Time to progression or progression-free survival is defined as the time from the dosimetric dose to the first documented occurrence of disease progression or death. Disease progression is defined as a >=50% increase from the nadir value (lowest laboratory value recorded following administration of the study medication) of the sum of the products of the longest perpendicular diameters of all measurable lesions or the appearance of any new lesion. Individual lesions must be >1.5 cm in diameter by radiographic evaluation or >1 cm in diameter by physical examination. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Time to Treatment Failure, as Assessed by the Investigator

Time to treatment failure is defined as the time from the start of treatment to the first occurrence of study withdrawal, progression, or death. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Total Body Residence Time (TBRT; Average Amount of Time TST Spends in the Body, Calculated From the Rate of TB Clearance of Radioactivity During the Dosimetric Dose [DD]) of Iodine 131 TST Antibody Following the DD

To determine TBRT, the percent-injected activity (PIA) is calculated from the background-corrected (BC) total body count (TBC) at D 0; D 2/3/4; and D 7. The time from the DD to the acquisition of whole body count (WBC) is then determined. The PIA remaining at each time point (TP) is then calculated by dividing the BC WBC for that TP by the BC WBC from the first TP (D 0) * 100. To determine RT, a best-fit line from 100% (pre-plotted D 0 value) through 2 plotted points (other TPs) is made. TBRT=the x-axis value at the point where the line intersects the horizontal 37% injected activity line. (NCT01663714)
Timeframe: Day (D) 0; D 2, 3, or 4; and D 6 or 7

DOR for Unconfirmed and Confirmed Complete Response, as Assessed by the Investigator

DOR=the time from the first documented response (for par. with CR) until disease progression (DP). DP=a >=50% increase from the nadir value (lowest laboratory value recorded following administration of study medication) of the sum of the products of the longest perpendicular diameters of all measurable lesions or the appearance of any new lesion. Individual lesions must be >1.5 centimeters (cm) in diameter by radiographic evaluation or >1 cm in diameter by physical examination. Responses had to be confirmed by 2 separate evaluations occurring >=4 weeks apart. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Duration of Response (DOR), as Assessed by the Investigator

DOR=the time from the first documented response (for par. with CR, CRu, or PR) until disease progression (DP). DP=a >=50% increase from the nadir value (lowest laboratory value recorded following administration of study medication) of the sum of the products of the longest perpendicular diameters of all measurable lesions or the appearance of any new lesion. Individual lesions must be >1.5 centimeters (cm) in diameter by radiographic evaluation or >1 cm in diameter by physical examination. Responses had to be confirmed by 2 separate evaluations occurring >=4 weeks apart. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Number of Participants Who Were Negative for Human Anti-murine Antibodies (HAMA) at Baseline (Study Entry) But Positive or Negative at Month 24

"The administration of murine antibodies may form HAMA. A HAMA assay was performed using the ImmunoSTRIP HAMA IgG enzyme-linked immune absorbent assay by a central laboratory (Covance Classic Laboratory Services, Indianapolis, IN). To be positive, a participant had to have a positive HAMA assessment during the first 24 months." (NCT01663714)
Timeframe: Day 1 to Day 730 (24 months) after receiving the dosimetric dose

Number of Participants With Any Treatment-related Serious Adverse Event (SAE)

An SAE is defined as any event occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse drug experience (at immediate risk of death from the experience as it occurred), inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life threatening, or require hospitalization may be considered to be a serious adverse drug experience when based upon appropriate medical judgment. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Number of Participants With the Indicated Grade 3 or Grade 4 Adverse Events (AEs)

AEs were graded using the Common Toxicity Criteria from the Cancer Therapy Evaluation Program, Division of Cancer Therapy, National Cancer Institute. Grades: 0 = No AE or within normal limits; 1 = Mild AE; 2 = Moderate AE; 3 = Severe and undesirable AE; 4 = Life-threatening or disabling AE; 5 = Death related to AE. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Number of Participants With the Indicated Grade 3 or Grade 4 AEs Possibly or Probably Related to Study Drug

AEs were graded using the Common Toxicity Criteria from the Cancer Therapy Evaluation Program, Division of Cancer Therapy, National Cancer Institute. Grades: 0 = No AE or within normal limits; 1 = Mild AE; 2 = Moderate AE; 3 = Severe and undesirable AE; 4 = Life-threatening or disabling AE; 5 = Death related to AE. The Investigator assessed whether the AE was possibly or probably related to study drug. In addition, all laboratory-derived hematologic toxicities (values outside the normal range) were assumed to be possibly or probably related to study drug. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Number of Participants With the Indicated Primary Cause of Death

The primary cause of death of the participants was assessed by the Investigator. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.

Time to Nadir for Hematological Parameters: Absolute Neutrophil Count (ANC), Hemoglobin, Platelets, and White Blood Cell (WBC) Count

Time to Recovery (TTR) to Baseline (BL) for Hematologic Laboratory (Lab.) Evaluations

TTR to BL grade (gr.) for par. with a Gr. 0 toxicity (tox.=lab. value outside the normal range) at BL=time from the last administration of study drug (SD) to the first post-nadir (PN) date with Gr. 0 toxicity with no other Gr. 1-4 toxicities recorded within the next week. For par. with a higher gr. tox. at BL, TTR=time from the last administration of SD to the first PN date with the BL gr. or better with no other higher gr. toxicities recorded during the next week. Each lab. established its own reference range using data from its own equipment/methods; there is no standard reference range. (NCT01663714)
Timeframe: Up to 120 days following the therapeutic dose (given on Study Day 7, following the dosimetric dose) (or the dosimetric dose for participants who did not receive the therapeutic dose)

CL After the Sixth Infusion (Week 15, Visit 22)

CL is the clearance of drug from plasma, which is defined as the volume of plasma from which the drug is cleared per unit time. (NCT00494780)
Timeframe: Week 15 (Visit 22)

Duration of Response

The duration of response is defined as the time from the initial response (the first visit at which response was observed) to progression or death. (NCT00494780)
Timeframe: Followed up to 5 years

Half Life (t1/2) of Ofatumumab at the Sixth Infusion (Week 15, Visit 22)

Half life is defined as the period of time required for the amount of drug in the body to be reduced by half. (NCT00494780)
Timeframe: Week 15 (Visit 22)

Median Percent Change From Visit 1 (Screening) in Serum Complement (CH50) Levels at Visit 22

The peripheral blood for each participant was collected and analyzed for serum complement CH50 levels. Cluster of Differentiation index 50 (CD50) is a human gene which is used as an index of immune response. CD50Percent change from Visit 1 (Screening, Week -2) = (value at Visit 22 minus value at Visit 1 divided by value at Visit 1) * 100. (NCT00494780)
Timeframe: Visit 1 (Screening, Week -2) and Visit 22 (Week 15)

Number of Participants Who Experienced Any Adverse Event (AEs) From First Treatment to Visit 33 (24 Months After Last Infusion)

An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. A list of AEs experienced in the study with a frequency threshold of 5% can be found in the AE section. (NCT00494780)
Timeframe: Up to 22 months after study start

Number of Participants With Complete Remission (CR) at Visit 26

Participants were evaluated for response by an Independent Endpoint Review Committee in accordance with the standardized response criteria for NHL. Participants with CR were defined as those with the complete disappearance of all detectable clinical and radiographic evidence of disease. (NCT00494780)
Timeframe: Maximum of 23 months after the start of treatment

Progression-Free Survival (PFS)

PFS is defined as the time from randomization until progression or death. (NCT00494780)
Timeframe: Followed up to 5 years

Time to New Anti-follicular Lymphoma (FL) Therapy

Time to new FL therapy is defined as the time from randomization until the time of first administration of the new FL therapy other than ofatumumab. Time to new FL therapy will be censored if participants are lost to follow-up. The censoring date in such cases will be the date of the last attended visit at which the endpoint was assessed. (NCT00494780)
Timeframe: Followed up to 5 years

Vss at the Sixth Infusion (Week 15, Visit 22)

Vss is defined as the volume of distribution at steady state of ofatumumab. (NCT00494780)
Timeframe: Week 15 (Visit 22)

AUC(0-inf) and AUC(0-504) After the Sixth Infusion (Week 15, Visit 22)

AUC is defined as the area under the ofatumumab concentration-time curve as a measure of drug exposure. AUC(0-504) is AUC from the start of infusion to 504 hours after the start of the infusion; AUC(0-inf) is AUC from the start of infusion extrapolated to infinity. (NCT00494780)
Timeframe: Week 15 (Visit 22)

Cmax and Ctrough at the Sixth Infusion (Week 15, Visit 22)

Cmax is defined as the maximum concentration of drug in plasma samples. Ctrough is defined as the trough plasma concentration (measured concentration at the end of a dosing interval [taken directly before next administration]). (NCT00494780)
Timeframe: Week 15 (Visit 22)

Median Percent Change From Visit 1 (Screening, Week -2) in Tumor Size at Visit 33 (24 Months After the Last Infusion of Ofatumumab)

The tumor size for a participant was computed as the sum of product of diameters (SPD) for the indicator lesions. Reduction in tumor size was calculated as percent change from Visit 1 until Visit 33, separately by radiologist 1 and radiologist 2. Percent change from Visit 1 (Screening, Week -2) = (value at Visit 33 minus value at Visit 1 divided by value at Visit 1) * 100. (NCT00494780)
Timeframe: Maximum of 24 months after the last infusion of Ofatumumab (Visit 33; median of 33.8 months)

Number of Participants With Positive Human Anti-human Antibodies (HAHA) at Visits 1, 28, and 33

HAHA are indicators of immunogenicity to ofatumumab. Blood samples were drawn from participants at Visits 1, 28, and 33 for analysis of HAHA. (NCT00494780)
Timeframe: Visits 1 (Screening), 28 (9 months after last dose), and 33 (24 months after last dose)

Number of Participants With the Indicated Overall Best Response (OBR) at Visit 26 (3 Months After the Last Infusion of Ofatumumab)

Based on standardized response criteria for NHL, responders included participants with CR (complete disappearance of all detectable clinical and radiographic evidence of disease), CRu (more than a 75% decrease in LN size compared to baseline), and PR (>=50% decrease in LN size and evidence of new lesions). Non-responders included participants with stable disease (SD; <50% decrease in LN size from baseline) and progressive disease (PD; >=50% increase in LN size and evidence of new lesions). (NCT00494780)
Timeframe: Maximum of 23 months after the start of treatment

Percent Change From Visit 1 (Screening) in Peripheral CD19+ and CD20+ Cell Counts at Visit 33 (24 Months After the Last Infusion of Ofatumumab)

The peripheral blood for each participant was collected and analyzed for CD19+ and CD20+ cell counts. CD19+ and CD20+ are B-cell types which are used as an index of a participant's response to treatment. (NCT00494780)
Timeframe: Maximum of 24 months after the last infusion of Ofatumumab (Visit 33; median of 33.8 months)

Count of Participants With Serious and Non-Serious Adverse Events

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00114738)
Timeframe: Date treatment consent signed to date off study, approximately 143 months and 7 days

Median Overall Survival (OS)

Overall Survival is the time between the first day of treatment to the day of death. The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 9.9 years

Overall Progression Free Survival

Time interval from start of treatment to documented evidence of disease progression. Progression is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes, appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin, appearance of new palpable hepatomegaly or splenomegaly that was not previously present, and ≥50% increase in the absolute number of circulating lymphocytes. (NCT00114738)
Timeframe: up to 9.9 years

Overall Survival

Progression Free Survival (PFS)

Clinical Response

Clinical response is assessed by the response criteria for lymphomas and is defined as a fraction of patients who have a complete response (CR) or a complete response (CR) + partial response (PR). A complete response is disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g. lactate dehydrogenase) definitely assignable to the lymphoma. Partial response is ≥50% decreased in the sum of the products of the greatest diameters of 6 largest dominant nodes or nodal masses. No increase in size of nodes, liver or spleen and no new sites of disease. Progressive disease is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen, ≥50% increase in the absolute number of circulating lymphocytes. (NCT00114738)
Timeframe: up to 22 weeks after initiation of therapy

Intervention	Participants (Count of Participants)
Ublituximab Only	2
Ublituximab First, Then Ublituximab and Umbralisib	2

Intervention	Participants (Count of Participants)
Ublituximab Only	2
Ublituximab First, Then Ublituximab and Umbralisib	2

Intervention	months (Median)
	Unconfirmed Responders with CR	Confirmed Responders with CR
Chemotherapy; TST and Iodine I 131 TST	129.6	129.6

Intervention	months (Median)
	Unconfirmed Responders	Confirmed Responders
Chemotherapy; TST and Iodine I 131 TST	129.6	129.6

Intervention	participants (Number)
	Febrile neutropenia	Anaemia	Neutropenia	Thrombocytopenia	Granulocytopenia	Leukopenia	Acute myeloid leukaemia	Basal cell carcinoma	Myelodysplastic syndrome	Squamous cell carcinoma	Perirectal abscess	Neutropenic infection	Pyrexia	Cystitis hemorrhagic
Chemotherapy; TST and Iodine I 131 TST	5	2	2	2	1	1	2	1	1	1	2	1	1	1

Intervention	participants (Number)
	ANC <1000 cells/mm^3	WBC <2000 cells/mm^3	Platelets <50000 cells/mm^3	Hemoglobin <8.0 g/dL	Neutropenia	Leukopenia	Febrile neutropenia	Thrombocytopenia	Anemia	Granulocytopenia	Lymphopenia	Alopecia	Night sweats	Acute myeloid leukaemia	Basal cell carcinoma	Myelodysplastic syndrome	Prostate cancer	Squamous cell carcinoma	Perirectal abscess	Urinary tract infection	Cystitis	Neutropenic infection	Otitis media	Periorbital cellulitis	Aphasia	Cerebrovascular accident	Headache	Hypoaesthesia	VIIth nerve paralysis	Asthenia	Pyrexia	Myalgia	Pain in extremity	Depression	Insomnia	Amenorrhoea	Breast mass	Conjunctivitis	Constipation	Drug hypersensitivity	Aspartate aminotransferase increased	Cystitis hemorrhagic	Epistaxis
Chemotherapy; TST and Iodine I 131 TST	29	23	12	2	15	6	5	4	3	1	1	9	1	2	2	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

Intervention	participants (Number)
	Progression of lymphoma	Complications related to study drug	Other
Chemotherapy; TST and Iodine I 131 TST	5	1	3

Intervention	days (Median)
	ANC	Hemoglobin	Platelets	WBC count
Chemotherapy; TST and Iodine I 131 TST	49.0	49.0	35.5	44.0

Intervention	days (Median)
	Time to recovery to baseline ANC, n=30	Time to recovery to baseline hemoglobin, n=28	Time to recovery to baseline platelets, n=30	Time to recovery to baseline WBC count, n=29
Chemotherapy; TST and Iodine I 131 TST	77.0	76.5	60.5	126.5

Intervention	Milligrams * hours/liter (mg.h/L) (Geometric Mean)
	AUC(0-inf), n=20, 28	AUC(0-504), n=24, 28
1000 mg Ofatumumab + CHOP	399676	168866
500 mg Ofatumumab + CHOP	177133	79500

Intervention	milligrams per liter (mg/L) (Geometric Mean)
	Cmax	Ctrough
1000 mg Ofatumumab + CHOP	497	188
500 mg Ofatumumab + CHOP	232	78.5

Intervention	Percent change in tumor size (Median)
	Radiologist 1	Radiologist 2
1000 mg Ofatumumab + CHOP	-100	-100
500 mg Ofatumumab + CHOP	-100	-100

Intervention	participants (Number)
	Visit 1, n=29, 29	Visit 28, n=18, 21	Visit 33, n=16, 16
1000 mg Ofatumumab + CHOP	0	0	0
500 mg Ofatumumab + CHOP	0	0	0

Intervention	participants (Number)
	Responder, CR	Responder, CRu	Responder, PR	Non-Responder, SD	Non-Responder, PD
1000 mg Ofatumumab + CHOP	9	7	13	0	0
500 mg Ofatumumab + CHOP	6	10	10	2	1

Intervention	Percent change in cell counts (Median)
	CD19+	CD20+
1000 mg Ofatumumab + CHOP	307.9	307.9
500 mg Ofatumumab + CHOP	154.1	154.1

Intervention	Percentage of patients (Number)
	Overall Response (CR+PR)	Complete Response	Stable Disease	Progressive Disease	Not Evaluable
EPOCH-R+Bortezomib	92.5	86.7	3.8	1.9	1.9